title: The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment.
abstract: Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program(®) (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, "Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.
authors.affiliation: National Marrow Donor Program®, 3001 Broadway Street NE, Minneapolis, MN 55413, USA.
authors.forename: Navneet S
authors.initials: NS
authors.lastname: Majhail
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Murphy
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Denzen
authors.forename: Stacy Stickney
authors.initials: SS
authors.lastname: Ferguson
authors.forename: Stacy S
authors.initials: SS
authors.lastname: Ferguson
authors.forename: Claudio
authors.initials: C
authors.lastname: Anasetti
authors.forename: Arthur
authors.initials: A
authors.lastname: Bracey
authors.forename: Linda
authors.initials: L
authors.lastname: Burns
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Norman
authors.initials: N
authors.lastname: Hubbard
authors.forename: Miriam
authors.initials: M
authors.lastname: Markowitz
authors.forename: Richard T
authors.initials: RT
authors.lastname: Maziarz
authors.forename: Erin
authors.initials: E
authors.lastname: Medoff
authors.forename: Joyce
authors.initials: J
authors.lastname: Neumann
authors.forename: Kim
authors.initials: K
authors.lastname: Schmit-Pokorny
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: Deborah S
authors.initials: DS
authors.lastname: Yolin Raley
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Chell
authors.forename: Edward L
authors.initials: EL
authors.lastname: Snyder
mesh_terms: D001853:Bone Marrow; D003226:Congresses as Topic; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D009313:National Health Programs; D009369:Neoplasms / Q000628:therapy; D014019:Tissue Donors; D014481:United States